ING Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.71M Sell
45,160
-151,468
-77% -$20M 0.03% 304
2026
Q1
$27.4M Sell
196,628
-167,726
-46% -$23.5M 0.17% 105
2025
Q4
$44.7M Buy
364,354
+177,642
+95% +$21.6M 0.27% 73
2025
Q3
$20.7M Sell
186,712
-100,856
-35% -$11.5M 0.11% 124
2025
Q2
$31.9M Sell
287,568
-27,460
-9% -$2.92M 0.19% 81
2025
Q1
$35.3M Buy
315,028
+55,645
+21% +$5.74M 0.24% 72
2024
Q4
$24M Sell
259,383
-133,302
-34% -$12M 0.16% 103
2024
Q3
$32.9M Buy
392,685
+109,788
+39% +$8.38M 0.19% 89
2024
Q2
$19.4M Sell
282,897
-19,031
-6% -$1.27M 0.12% 136
2024
Q1
$22.1M Sell
301,928
-630,040
-68% -$48.4M 0.15% 120
2023
Q4
$75.5M Buy
931,968
+457,847
+97% +$35.6M 0.61% 28
2023
Q3
$35.5M Sell
474,121
-300,791
-39% -$23.1M 0.31% 69
2023
Q2
$59.7M Buy
774,912
+534,194
+222% +$42.6M 0.45% 45
2023
Q1
$20M Sell
240,718
-94,714
-28% -$7.84M 0.19% 100
2022
Q4
$28.8M Buy
335,432
+46,694
+16% +$3.7M 0.29% 71
2022
Q3
$17.8M Sell
288,738
-27,709
-9% -$1.75M 0.3% 72
2022
Q2
$19.6M Buy
316,447
+36,811
+13% +$2.28M 0.23% 81
2022
Q1
$16.6M Buy
279,636
+54,889
+24% +$3.51M 0.17% 103
2021
Q4
$16.3M Buy
224,747
+91,288
+68% +$6.29M 0.15% 128
2021
Q3
$9.32M Buy
133,459
+2,748
+2% +$193K 0.12% 126
2021
Q2
$9M Buy
130,711
+41,923
+47% +$2.8M 0.14% 107
2021
Q1
$5.74M Buy
88,788
+3,643
+4% +$235K 0.12% 113
2020
Q4
$4.96M Buy
85,145
+55,398
+186% +$3.34M 0.11% 124
2020
Q3
$1.88M Buy
29,747
+16,488
+124% +$1.14M 0.08% 133
2020
Q2
$1.02M Sell
13,259
-130,973
-91% -$10M 0.04% 123
2020
Q1
$10.8M Buy
144,232
+58,773
+69% +$4.06M 0.46% 37
2019
Q4
$5.55M Buy
85,459
+6,423
+8% +$418K 0.17% 102
2019
Q3
$5.01M Sell
79,036
-299,719
-79% -$19.6M 0.13% 122
2019
Q2
$25.6M Buy
378,755
+297
+0.1% +$19.5K 0.45% 45
2019
Q1
$24.6M Buy
378,458
+39,568
+12% +$2.63M 0.53% 33
2018
Q4
$21.2M Buy
338,890
+3,456
+1% +$242K 0.46% 47
2018
Q3
$25.9M Buy
335,434
+12,700
+4% +$959K 0.45% 48
2018
Q2
$22.9M Buy
322,734
+236,424
+274% +$16.7M 0.44% 41
2018
Q1
$6.51M Buy
86,310
+82,008
+1,906% +$6.52M 0.12% 105
2017
Q4
$308K Sell
4,302
-470,389
-99% -$35.7M 0.01% 637
2017
Q3
$38.5M Buy
474,691
+37,698
+9% +$2.88M 0.74% 33
2017
Q2
$30.9M Sell
436,993
-15,789
-3% -$1.05M 0.59% 30
2017
Q1
$30.8M Buy
452,782
+80,061
+21% +$5.63M 0.56% 38
2016
Q4
$26.9M Sell
372,721
-35,169
-9% -$2.61M 0.5% 39
2016
Q3
$31.8M Buy
407,890
+275,666
+208% +$22.4M 0.38% 47
2016
Q2
$11M Sell
132,224
-748,634
-85% -$66.4M 0.15% 81
2016
Q1
$80.7M Sell
880,858
-1,892,412
-68% -$171M 1.01% 21
2015
Q4
$281M Buy
2,773,270
+978,546
+55% +$102M 1.69% 6
2015
Q3
$176M Buy
1,794,724
+216,203
+14% +$24M 1.22% 13
2015
Q2
$185M Buy
1,578,521
+183,994
+13% +$20.1M 1% 17
2015
Q1
$137M Sell
1,394,527
-55,543
-4% -$5.64M 0.69% 27
2014
Q4
$137M Buy
1,450,070
+356,778
+33% +$36.9M 0.64% 29
2014
Q3
$116M Buy
1,093,292
+450,825
+70% +$44.1M 0.68% 29
2014
Q2
$53.3M Buy
642,467
+292,087
+83% +$22.7M 0.27% 81
2014
Q1
$24.8M Buy
350,380
+240,958
+220% +$18.9M 0.13% 169
2013
Q4
$8.22M Buy
109,422
+87,265
+394% +$6.08M 0.04% 310
2013
Q3
$1.39M Buy
22,157
+6,707
+43% +$401K 0.01% 530
2013
Q2
$791K Buy
+15,450
New +$805K ﹤0.01% 562

Other funds holding GILD

ING Group's GILD Position: Q2 2026 in Review

ING Group reduced its Gilead Sciences (GILD) stake by 77% in Q2 2026, selling an estimated $20M and leaving 45,160 shares worth $5.71M. The position accounts for 0.03% of the portfolio, ranked #304.

ING Group first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $281M in Q4 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • ING Group held 45,160 shares of Gilead Sciences worth $5.71M as of Q2 2026.
  • ING Group sold 151,468 Gilead Sciences shares in Q2 2026, an estimated $20M.
  • Gilead Sciences made up 0.03% of ING Group's portfolio in Q2 2026, its #304 holding.
  • ING Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • ING Group's Gilead Sciences position peaked at $281M in Q4 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.